Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1167-1168

  Madan, Ravi A ^a   Heery, Christopher R ^a   Gulley, James L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Ipilimumab; Prostate cancer; PROSTVAC; PSA TRICOM; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PSA TRICOM; SIPULEUCEL T; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELLULAR IMMUNITY; COLITIS; DRUG DOSE ESCALATION; DRUG ERUPTION; ENDOCRINE DISEASE; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNOREGULATION; MAXIMUM TOLERATED DOSE; METASTATIC MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

EID: 84885733818     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20591     Document Type: Article

References (10)

1. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. [Epub ahead of print]. Lancet Oncol 2012; 13:501-8; PMID:22326924; http://dx.doi.org/10.1016/S1470-2045(12)70006-2.
2. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294.
3. Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances, lessons learned and areas for further research. Clin Cancer Res 2011; 17:3884-91; PMID:21680544; http://dx.doi.org/10.1158/1078-0432.CCR-10-2656.
4. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099-105; PMID:20100959; http://dx.doi.org/10.1200/JCO.2009.25.0597.
5. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3:611-8; PMID:12087419; http://dx.doi.org/10.1038/ni0702-611.
6. Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J. Multiple costimulatory modalities enhance CTL avidity. J Immunol 2005; 174:5994-6004; PMID:15879092.
7. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.
8. von Mehren M, Arlen P, Tsang KY, Rogatko A, Meropol N, Cooper HS, et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 2000; 6:2219-28; PMID:10873071.
9. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59:663-74; PMID:19890632; http://dx.doi.org/10.1007/s00262-009-0782-8.
10. Kudo-Saito C, Schlom J, Hodge JW. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res 2005; 11:2416-26; PMID:15788693; http://dx.doi.org/10.1158/1078-0432.CCR-04-1380.